Skip to main content

Nipah Virus Infection

4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
267%
Vaccine
133%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Public Health Vaccines
2 programs
2
PHV02Phase 11 trial
PHV02Phase 11 trial
Active Trials
NCT06221813Completed120Est. Oct 2024
NCT05178901Completed60Est. May 2023
Auro Vaccines
Auro VaccinesNY - Pearl River
1 program
1
Nipah Virus VaccinePhase 1Vaccine1 trial
Active Trials
NCT04199169Completed192Est. May 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
mRNA -1215Phase 1RNA Therapeutic1 trial
Active Trials
NCT05398796Completed40Est. Sep 2024
Moderna
ModernaCAMBRIDGE, MA
1 program
mRNA -1215PHASE_1RNA Therapeutic

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Public Health VaccinesPHV02
Allergy TherapeuticsmRNA -1215
Public Health VaccinesPHV02
Auro VaccinesNipah Virus Vaccine

Clinical Trials (4)

Total enrollment: 412 patients across 4 trials

NCT06221813Public Health VaccinesPHV02

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Start: Jan 2024Est. completion: Oct 2024120 patients
Phase 1Completed
NCT05398796Allergy TherapeuticsmRNA -1215

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Start: Jul 2022Est. completion: Sep 202440 patients
Phase 1Completed
NCT05178901Public Health VaccinesPHV02

A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Start: Jan 2022Est. completion: May 202360 patients
Phase 1Completed
NCT04199169Auro VaccinesNipah Virus Vaccine

Safety and Immunogenicity of a Nipah Virus Vaccine

Start: Feb 2020Est. completion: May 2022192 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

RNA Therapeutic is the dominant modality (67% of programs)
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.